gefitinib has been researched along with Uterine Cervical Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Y; Li, Q; Liu, F; Wang, H; Wang, Y | 1 |
| Athiyamaan, MS; Banerjee, S; Jawahar, V; Krishna, A; Lobo, D; Makkapatti, BS; Mukesh, S; Sathya, M; Srinivas, C; Sunny, J | 1 |
| Gandhi, AK; Jagadesan, P; Julka, PK; Kumar, S; Rath, GK; Sharma, DN | 1 |
| Du, J; Hu, H; Li, C; Li, H; Li, Y; Wang, L; Yang, H; Zhang, Z | 1 |
| Arora, H; Biswas, S; Gandhi, G; Naseem, A; Perwez, A; Qureshi, R; Rizvi, MA; Wajid, S | 1 |
| Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P | 1 |
| Al Moustafa, AE | 1 |
2 trial(s) available for gefitinib and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Female; Gefitinib; Humans; India; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Uterine Cervical Neoplasms | 2013 |
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms | 2008 |
5 other study(ies) available for gefitinib and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
SEC61G Promotes Cervical Cancer Proliferation by Activating MAPK Signaling Pathway.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; SEC Translocation Channels; Signal Transduction; Uterine Cervical Neoplasms | 2022 |
Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Topics: Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Uterine Cervical Neoplasms | 2023 |
MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromones; Enzyme Inhibitors; Female; Gefitinib; HeLa Cells; Humans; MicroRNAs; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Uterine Cervical Neoplasms | 2016 |
Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; HeLa Cells; Human papillomavirus 16; Human papillomavirus 18; Humans; India; Middle Aged; Mutation; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Uterine Cervical Neoplasms | 2016 |
Human cervical carcinomas and EGF-R tyrosine kinase inhibitors.
Topics: Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Uterine Cervical Neoplasms | 2008 |